Basis: FMP quote price / unrounded FMP forward EPS in the trading currency, available after its recorded retrieval time. Source: stored company filings and market data; unavailable inputs remain N/A.
The forward PE ratio is 19.71 as of 2026-09-18T08:15:56.630Z.
Consensus retrieved: 2026-09-13T23:21:39.869Z. This records retrieval, including cache reads, rather than vendor publication. The calculation uses the separately dated price and estimate available at its as-of time.
Calculation as of: 2026-09-18T08:15:56.630Z.
Quote observation: 2026-09-17T20:00:02.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 85eef12130a48b0cf44c76688118bc638692902120f757679f8e8036b24ed865
Forward PE Ratio (19.71) = Dated Quote Price ($879.57) / Consensus Forward EPS ($44.63)
FORWARD PE RATIO
19.71
SECTOR MEDIAN · HEALTHCARE
18.94
median of 76 covered companies
CURRENT VS SECTOR MEDIAN
+4.07%
vs the sector median at left
McKesson Corporation
Market Cap
$102.98B
Forward PE Ratio
19.71
| NAME | MARKET CAP | FORWARD PE RATIO |
|---|---|---|
| McKesson Corporation (MCK) | $102.98B | 19.71 |
| Sanofi (SNY)vs › | $103.59B | N/A |
| GSK plc (GSK)vs › | $102.30B | N/A |
| Stryker Corporation (SYK)vs › | $107.39B | 18.66 |
| HCA Healthcare, Inc. (HCA)vs › | $92.89B | 14.56 |
| CVS Health Corp. (CVS)vs › | $115.18B | 11.28 |
| Elevance Health Inc. (ELV)vs › | $89.84B | 15.26 |
| Medtronic plc (MDT)vs › | $118.75B | 15.53 |
| Regeneron Pharmaceuticals, Inc. (REGN)vs › | $81.33B | 14.48 |
| Bristol-Myers Squibb Company (BMY)vs › | $128.36B | 9.07 |
Trailing P/E
23.5
reported TTM EPS
Forward P/E
19.7
consensus EPS · fiscal year ending 2027-03-31
The gap between the two multiples is the consensus growth expectation: analysts' forward EPS of $44.63 implies +19.4% EPS growth vs the reported trailing $37.37.
At the dated quote price of $879.57, each upcoming fiscal year's consensus EPS implies a different multiple — how quickly the price is "paid down" by expected earnings if the estimates hold.
| Fiscal year end | Consensus EPS | Estimate range | Analysts | Implied P/E |
|---|---|---|---|---|
| 2027-03-31 | $44.63 | $44.28 – $45.23 | 9 | 19.7x |
| 2028-03-31 | $50.55 | $47.45 – $51.34 | 9 | 17.4x |
| 2029-03-31 | $57.77 | $55.68 – $59.61 | 3 | 15.2x |
Source: FMP analyst consensus estimates, refreshed with the daily precompute. "n/m" = the consensus EPS is not positive, so a multiple is undefined. There is no forward P/E history chart here because charting one would require the estimates as they stood in the past, which we do not store — see the trailing P/E history for how the realized multiple has moved.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
